Filing Overview
This Form 6-K was filed by I-MAB, a foreign private issuer, for the month of March 2022 and dated March 29, 2022. The filing identifies I-MAB’s principal executive offices in Shanghai, China and references an attached Exhibit 99.1 press release; the press release text is not included in the provided filing content.
Financial Metrics
The provided filing text does not disclose revenue, profit or loss, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Material Changes Versus Prior Period
The filing text does not provide information regarding changes from a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management commentary, risk factors, contingencies, or unusual items are disclosed in the provided text. Any such information may be contained in Exhibit 99.1, which is referenced but not supplied.
Investor Verification Items
- Verify the issuer identity: the filing names I-MAB, while the request metadata identifies Novabridge Biosciences.
- Obtain and review Exhibit 99.1, the referenced press release.
- Confirm whether the press release contains financial results, operational updates, guidance, or material events.
- Verify the filing date, reporting period, and any information incorporated by reference.